Key result
Remdesivir administration in three COVID-19 patients was associated with significant bradycardia and QTc prolongation that resolved after discontinuation of the drug.
Case Report (n=3)
No
Remdesivir administration in COVID-19 patients may be associated with significant bradycardia and QTc prolongation requiring intervention and careful monitoring.
Remdesivir may induce bradycardia and QTc prolongation requiring intervention; hypothesis-generating for cardiac safety monitoring in larger cohorts.
Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.
No takes yet. Share an insight, caveat, or question.
Shirvani et al. (2021) conducted a case report in COVID-19 (n=3). Remdesivir was evaluated on Development of significant bradycardia and QTc prolongation. Remdesivir administration in three COVID-19 patients was associated with significant bradycardia and QTc prolongation that resolved after discontinuation of the drug.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: